Skip to Content

Join the 'Ilaris' group to help and get support from people like you.

Ilaris News

New Drug, Canakinumab, May Fight Heart Disease in Whole New Way

Posted 28 Aug 2017 by

MONDAY, Aug. 28, 2017 – Move over, statins: New research finds that a medication aimed at dampening the body's inflammatory response may be a new tool to curb heart disease. The findings were presented Sunday at the European Society of Cardiology (ESC) Congress in Barcelona, Spain, and published in two major medical journals, The Lancet and the New England Journal of Medicine. The trial focused on a new drug called canakinumab, which lowered by 15 percent the overall rate of heart events such as heart attack, stroke and cardiovascular death in people who'd already had a heart attack. The people in the study also had high levels of a compound called C-reactive protein in their blood – a marker that is indicative of a heightened inflammatory response. For years, heart researchers have wondered if a drug that lowered inflammation might help curb heart disease. Cardiologists had mixed ... Read more

Related support groups: Heart Disease, Heart Attack, High Cholesterol, Lipitor, Simvastatin, Atorvastatin, Crestor, Pravastatin, Lovastatin, Zocor, Myocardial Infarction, Rosuvastatin, Hypertriglyceridemia, Red Yeast Rice, Pravachol, Prevention of Cardiovascular Disease, Livalo, Cardiovascular Risk Reduction, Thromboembolic Stroke Prophylaxis, Lescol XL

FDA Approves Expanded Indications for Ilaris (canakinumab) for Three Rare Periodic Fever Syndromes

Posted 26 Sep 2016 by

September 23, 2016 – The U.S. Food and Drug Administration today approved three new indications for Ilaris (canakinumab). The new indications are for rare and serious auto-inflammatory diseases in adult and pediatric patients: Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS); Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD); and Familial Mediterranean Fever (FMF). All three syndromes are hereditary diseases that are characterized by periodic attacks of fever and inflammation, as well as severe muscle pain. There are no previously approved therapies for TRAPS or HIDS/MKD. “For the first time, patients with TRAPS and HIDS/MKD, two painful and life altering diseases, have access to a treatment that may help improve their quality of life,” said Badrul Chowdhury, M.D., Ph.D, director of the Division of Pulmonary, Allergy and Rheumatology Products in ... Read more

Related support groups: Familial Mediterranean Fever, Ilaris, Canakinumab, Tumor Necrosis Factor Receptor Associated Periodic Syndrome, Hyperimmunoglobulin D Syndrome

New Treatments Helping Kids With Juvenile Arthritis

Posted 20 Jul 2016 by

WEDNESDAY, July 20, 2016 – New treatments for juvenile arthritis offer hope to children with the chronic autoimmune condition, doctors say. Scientists are still working to understand what causes juvenile arthritis and how to stop its progression. But, kids coping with its effects have reason to be optimistic, according to Dr. Nikolay Nikolov, a rheumatologist and clinical team leader at the U.S. Food and Drug Administration. "We don't have a cure for juvenile arthritis – we're not there yet," Nikolov said in an FDA news release. "But we're making progress." But it's important to note that the drugs aren't risk-free. Juvenile arthritis is one of the most common chronic childhood conditions, affecting nearly 300,000 children in the United States, according to the FDA. The disease causes the immune system to attack its own tissues, resulting in pain, swelling, tenderness and stiffness in ... Read more

Related support groups: Rheumatoid Arthritis, Aspirin, Ibuprofen, Humira, Advil, Enbrel, Motrin, Excedrin, Vicoprofen, Orencia, Alka-Seltzer, Aggrenox, Fiorinal, Excedrin Migraine, Actemra, Arthritis Pain, Juvenile Rheumatoid Arthritis, Advil PM, Advil Cold and Sinus, Ecotrin

Ilaris Approved by FDA to Treat Active Systemic Juvenile Idiopathic Arthritis

Posted 12 May 2013 by

Basel, May 10, 2013 - Novartis announced today that the US Food and Drug Administration (FDA) has approved Ilaris (canakinumab) for the treatment of active systemic juvenile idiopathic arthritis (SJIA) in patients aged 2 years and older. Ilaris is the first interleukin-1 beta (IL-1 beta) inhibitor approved for SJIA and the only treatment approved specifically for SJIA that is given as a once-monthly subcutaneous injection[1]. SJIA is a rare and disabling form of childhood arthritis characterized by spiking fever, rash and arthritis that can affect children as young as 2 years old and can continue into adulthood[2],[3]. This approval was based on two Phase III trials in SJIA patients, aged 2-19, showing significant improvement in the majority of Ilaris-treated patients[1]. Study 1 showed that 84% of patients treated with one subcutaneous dose of Ilaris achieved the primary endpoint of ... Read more

Related support groups: Juvenile Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Ilaris, Canakinumab

Drugs Hold Promise for Severe Juvenile Arthritis Patients

Posted 19 Dec 2012 by

WEDNESDAY, Dec. 19 – Children who suffer from a rare and painful form of arthritis that's accompanied by fever and rashes may soon have more treatment options. Two studies published in the Dec. 20 issue of the New England Journal of Medicine suggest that two drugs – canakinumab and tocilizumab – reduce symptoms, including severe joint pain experienced by children with systemic juvenile idiopathic arthritis (JIA). "Systemic juvenile idiopathic arthritis is a form of severe arthritis which until a few years ago was treated mainly with corticosteroids which have known side effects, especially growth impairment," said Dr. Nicolino Ruperto, a pediatric rheumatologist at G. Gaslini Children's Hospital in Genoa and co-author of the studies. The research looked at the safety and effectiveness of the interleukin-1 inhibitor canakinumab and the interleukin-6 inhibitor tocilizumab. The disease ... Read more

Related support groups: Rheumatoid Arthritis, Actemra, Juvenile Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Tocilizumab, Ilaris, Canakinumab

Ask a Question

Further Information

Related Condition Support Groups

Familial Cold Autoinflammatory Syndrome, Familial Mediterranean Fever, Cryopyrin-Associated Periodic Syndromes, Hyperimmunoglobulin D Syndrome, Muckle Wells Syndrome, Tumor Necrosis Factor Receptor Associated Periodic Syndrome, Juvenile Idiopathic Arthritis

Ilaris Patient Information at